nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—Gallbladder disorder—Varenicline—nicotine dependence	0.0393	0.0477	CcSEcCtD
Sitaxentan—Cardiac flutter—Varenicline—nicotine dependence	0.0393	0.0477	CcSEcCtD
Sitaxentan—Chest wall pain—Varenicline—nicotine dependence	0.0353	0.0428	CcSEcCtD
Sitaxentan—Gingival pain—Varenicline—nicotine dependence	0.0296	0.0358	CcSEcCtD
Sitaxentan—Vitreous floaters—Varenicline—nicotine dependence	0.0284	0.0345	CcSEcCtD
Sitaxentan—Pleurisy—Varenicline—nicotine dependence	0.0264	0.032	CcSEcCtD
Sitaxentan—Restless legs syndrome—Varenicline—nicotine dependence	0.0226	0.0274	CcSEcCtD
Sitaxentan—Joint stiffness—Varenicline—nicotine dependence	0.0214	0.0259	CcSEcCtD
Sitaxentan—Polydipsia—Varenicline—nicotine dependence	0.0208	0.0252	CcSEcCtD
Sitaxentan—Facial paralysis—Varenicline—nicotine dependence	0.0203	0.0246	CcSEcCtD
Sitaxentan—Musculoskeletal chest pain—Varenicline—nicotine dependence	0.0166	0.0202	CcSEcCtD
Sitaxentan—Drug hypersensitivity—Varenicline—nicotine dependence	0.016	0.0194	CcSEcCtD
Sitaxentan—Haematochezia—Varenicline—nicotine dependence	0.016	0.0194	CcSEcCtD
Sitaxentan—VIIth nerve paralysis—Varenicline—nicotine dependence	0.0157	0.0191	CcSEcCtD
Sitaxentan—Hoarseness—Varenicline—nicotine dependence	0.0147	0.0178	CcSEcCtD
Sitaxentan—Pancreatitis acute—Varenicline—nicotine dependence	0.014	0.0169	CcSEcCtD
Sitaxentan—Sinus congestion—Varenicline—nicotine dependence	0.013	0.0157	CcSEcCtD
Sitaxentan—Throat irritation—Varenicline—nicotine dependence	0.0128	0.0155	CcSEcCtD
Sitaxentan—Night sweats—Varenicline—nicotine dependence	0.012	0.0145	CcSEcCtD
Sitaxentan—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0119	0.068	CbGpPWpGaD
Sitaxentan—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0109	0.062	CbGpPWpGaD
Sitaxentan—Psoriasis—Varenicline—nicotine dependence	0.0103	0.0124	CcSEcCtD
Sitaxentan—EDNRB—Peptide GPCRs—OPRM1—nicotine dependence	0.0101	0.0574	CbGpPWpGaD
Sitaxentan—Cyst—Varenicline—nicotine dependence	0.00965	0.0117	CcSEcCtD
Sitaxentan—Menorrhagia—Varenicline—nicotine dependence	0.00872	0.0106	CcSEcCtD
Sitaxentan—Fungal infection—Varenicline—nicotine dependence	0.00836	0.0101	CcSEcCtD
Sitaxentan—Gingivitis—Varenicline—nicotine dependence	0.00822	0.00997	CcSEcCtD
Sitaxentan—Dysphonia—Varenicline—nicotine dependence	0.00784	0.00951	CcSEcCtD
Sitaxentan—Endocrine disorder—Varenicline—nicotine dependence	0.00778	0.00944	CcSEcCtD
Sitaxentan—Eye irritation—Varenicline—nicotine dependence	0.00756	0.00916	CcSEcCtD
Sitaxentan—Disturbance in attention—Varenicline—nicotine dependence	0.00745	0.00903	CcSEcCtD
Sitaxentan—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.00739	0.0422	CbGpPWpGaD
Sitaxentan—Chest discomfort—Varenicline—nicotine dependence	0.00729	0.00884	CcSEcCtD
Sitaxentan—EDNRA—Peptide GPCRs—OPRM1—nicotine dependence	0.00719	0.041	CbGpPWpGaD
Sitaxentan—Ventricular extrasystoles—Varenicline—nicotine dependence	0.00714	0.00866	CcSEcCtD
Sitaxentan—Viral infection—Varenicline—nicotine dependence	0.00714	0.00866	CcSEcCtD
Sitaxentan—Thinking abnormal—Varenicline—nicotine dependence	0.00705	0.00855	CcSEcCtD
Sitaxentan—Lacrimation increased—Varenicline—nicotine dependence	0.007	0.00849	CcSEcCtD
Sitaxentan—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00674	0.0384	CbGpPWpGaD
Sitaxentan—Musculoskeletal pain—Varenicline—nicotine dependence	0.00653	0.00792	CcSEcCtD
Sitaxentan—Pulmonary embolism—Varenicline—nicotine dependence	0.00645	0.00782	CcSEcCtD
Sitaxentan—Blood pressure increased—Varenicline—nicotine dependence	0.00645	0.00782	CcSEcCtD
Sitaxentan—Hyperkalaemia—Varenicline—nicotine dependence	0.00634	0.00769	CcSEcCtD
Sitaxentan—Eructation—Varenicline—nicotine dependence	0.00634	0.00769	CcSEcCtD
Sitaxentan—Photophobia—Varenicline—nicotine dependence	0.00606	0.00735	CcSEcCtD
Sitaxentan—Dry eye—Varenicline—nicotine dependence	0.00596	0.00723	CcSEcCtD
Sitaxentan—EDNRB—GPCR ligand binding—TAS2R16—nicotine dependence	0.00573	0.0327	CbGpPWpGaD
Sitaxentan—Mental disability—Varenicline—nicotine dependence	0.0056	0.00679	CcSEcCtD
Sitaxentan—Sleep disorder—Varenicline—nicotine dependence	0.00541	0.00656	CcSEcCtD
Sitaxentan—Deafness—Varenicline—nicotine dependence	0.00524	0.00635	CcSEcCtD
Sitaxentan—Increased appetite—Varenicline—nicotine dependence	0.00499	0.00604	CcSEcCtD
Sitaxentan—Menopausal symptoms—Varenicline—nicotine dependence	0.00496	0.00602	CcSEcCtD
Sitaxentan—Visual disturbance—Varenicline—nicotine dependence	0.00494	0.00599	CcSEcCtD
Sitaxentan—Arthritis—Varenicline—nicotine dependence	0.00482	0.00584	CcSEcCtD
Sitaxentan—Hypoglycaemia—Varenicline—nicotine dependence	0.0048	0.00582	CcSEcCtD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00473	0.027	CbGpPWpGaD
Sitaxentan—Osteoarthritis—Varenicline—nicotine dependence	0.00468	0.00568	CcSEcCtD
Sitaxentan—Gastrointestinal haemorrhage—Varenicline—nicotine dependence	0.00468	0.00568	CcSEcCtD
Sitaxentan—Migraine—Varenicline—nicotine dependence	0.00461	0.00559	CcSEcCtD
Sitaxentan—CYP3A4—Xenobiotics—CYP2A7—nicotine dependence	0.00444	0.0254	CbGpPWpGaD
Sitaxentan—Liver function test abnormal—Varenicline—nicotine dependence	0.00432	0.00524	CcSEcCtD
Sitaxentan—Dry skin—Varenicline—nicotine dependence	0.00429	0.00521	CcSEcCtD
Sitaxentan—Abdominal pain upper—Varenicline—nicotine dependence	0.00428	0.00519	CcSEcCtD
Sitaxentan—Breast disorder—Varenicline—nicotine dependence	0.00423	0.00513	CcSEcCtD
Sitaxentan—Cramp muscle—Varenicline—nicotine dependence	0.00422	0.00511	CcSEcCtD
Sitaxentan—EDNRA—GPCR ligand binding—TAS2R16—nicotine dependence	0.0041	0.0234	CbGpPWpGaD
Sitaxentan—Asthma—Varenicline—nicotine dependence	0.00405	0.00491	CcSEcCtD
Sitaxentan—Angina pectoris—Varenicline—nicotine dependence	0.00394	0.00478	CcSEcCtD
Sitaxentan—Bronchitis—Varenicline—nicotine dependence	0.00389	0.00472	CcSEcCtD
Sitaxentan—Abdominal discomfort—Varenicline—nicotine dependence	0.00388	0.00471	CcSEcCtD
Sitaxentan—Pollakiuria—Varenicline—nicotine dependence	0.00374	0.00453	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.0037	0.0211	CbGpPWpGaD
Sitaxentan—Photosensitivity reaction—Varenicline—nicotine dependence	0.0037	0.00448	CcSEcCtD
Sitaxentan—Hyperglycaemia—Varenicline—nicotine dependence	0.00365	0.00443	CcSEcCtD
Sitaxentan—Infestation—Varenicline—nicotine dependence	0.00361	0.00438	CcSEcCtD
Sitaxentan—Infestation NOS—Varenicline—nicotine dependence	0.00361	0.00438	CcSEcCtD
Sitaxentan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00356	0.00431	CcSEcCtD
Sitaxentan—Myocardial infarction—Varenicline—nicotine dependence	0.00354	0.00429	CcSEcCtD
Sitaxentan—Stomatitis—Varenicline—nicotine dependence	0.00352	0.00427	CcSEcCtD
Sitaxentan—Conjunctivitis—Varenicline—nicotine dependence	0.00351	0.00425	CcSEcCtD
Sitaxentan—Hepatobiliary disease—Varenicline—nicotine dependence	0.00341	0.00414	CcSEcCtD
Sitaxentan—Epistaxis—Varenicline—nicotine dependence	0.0034	0.00413	CcSEcCtD
Sitaxentan—Sinusitis—Varenicline—nicotine dependence	0.00339	0.00411	CcSEcCtD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—OPRM1—nicotine dependence	0.00338	0.0193	CbGpPWpGaD
Sitaxentan—Bradycardia—Varenicline—nicotine dependence	0.0033	0.004	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00324	0.0185	CbGpPWpGaD
Sitaxentan—Urinary tract disorder—Varenicline—nicotine dependence	0.0032	0.00388	CcSEcCtD
Sitaxentan—Oedema peripheral—Varenicline—nicotine dependence	0.00319	0.00387	CcSEcCtD
Sitaxentan—Urethral disorder—Varenicline—nicotine dependence	0.00318	0.00385	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00317	0.0181	CbGpPWpGaD
Sitaxentan—Visual impairment—Varenicline—nicotine dependence	0.00312	0.00379	CcSEcCtD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00307	0.0175	CbGpPWpGaD
Sitaxentan—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00303	0.0173	CbGpPWpGaD
Sitaxentan—Eye disorder—Varenicline—nicotine dependence	0.00303	0.00367	CcSEcCtD
Sitaxentan—Tinnitus—Varenicline—nicotine dependence	0.00302	0.00366	CcSEcCtD
Sitaxentan—Cardiac disorder—Varenicline—nicotine dependence	0.00301	0.00365	CcSEcCtD
Sitaxentan—Angiopathy—Varenicline—nicotine dependence	0.00294	0.00356	CcSEcCtD
Sitaxentan—EDNRB—Signaling by GPCR—TAS2R16—nicotine dependence	0.00294	0.0168	CbGpPWpGaD
Sitaxentan—Immune system disorder—Varenicline—nicotine dependence	0.00293	0.00355	CcSEcCtD
Sitaxentan—Mediastinal disorder—Varenicline—nicotine dependence	0.00292	0.00354	CcSEcCtD
Sitaxentan—Mental disorder—Varenicline—nicotine dependence	0.00284	0.00344	CcSEcCtD
Sitaxentan—Malnutrition—Varenicline—nicotine dependence	0.00282	0.00342	CcSEcCtD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.0028	0.016	CbGpPWpGaD
Sitaxentan—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00276	0.0158	CbGpPWpGaD
Sitaxentan—Muscle spasms—Varenicline—nicotine dependence	0.00271	0.00329	CcSEcCtD
Sitaxentan—EDNRB—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00268	0.0153	CbGpPWpGaD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00265	0.0151	CbGpPWpGaD
Sitaxentan—Tremor—Varenicline—nicotine dependence	0.00264	0.0032	CcSEcCtD
Sitaxentan—Ill-defined disorder—Varenicline—nicotine dependence	0.00262	0.00317	CcSEcCtD
Sitaxentan—Anaemia—Varenicline—nicotine dependence	0.00261	0.00316	CcSEcCtD
Sitaxentan—Agitation—Varenicline—nicotine dependence	0.00259	0.00314	CcSEcCtD
Sitaxentan—Malaise—Varenicline—nicotine dependence	0.00254	0.00308	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—FGD1—nicotine dependence	0.00254	0.0145	CbGpPWpGaD
Sitaxentan—Vertigo—Varenicline—nicotine dependence	0.00253	0.00307	CcSEcCtD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00249	0.0142	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—OPRM1—nicotine dependence	0.00241	0.0138	CbGpPWpGaD
Sitaxentan—Chest pain—Varenicline—nicotine dependence	0.0024	0.00291	CcSEcCtD
Sitaxentan—Unspecified disorder of skin and subcutaneous tissue—Varenicline—nicotine dependence	0.00238	0.00289	CcSEcCtD
Sitaxentan—Discomfort—Varenicline—nicotine dependence	0.00237	0.00288	CcSEcCtD
Sitaxentan—Dry mouth—Varenicline—nicotine dependence	0.00235	0.00285	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00232	0.0132	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—FGD1—nicotine dependence	0.00231	0.0132	CbGpPWpGaD
Sitaxentan—Oedema—Varenicline—nicotine dependence	0.0023	0.00279	CcSEcCtD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00229	0.0131	CbGpPWpGaD
Sitaxentan—Infection—Varenicline—nicotine dependence	0.00229	0.00277	CcSEcCtD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00227	0.0129	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00227	0.0129	CbGpPWpGaD
Sitaxentan—Nervous system disorder—Varenicline—nicotine dependence	0.00226	0.00274	CcSEcCtD
Sitaxentan—Thrombocytopenia—Varenicline—nicotine dependence	0.00225	0.00273	CcSEcCtD
Sitaxentan—Tachycardia—Varenicline—nicotine dependence	0.00225	0.00272	CcSEcCtD
Sitaxentan—Skin disorder—Varenicline—nicotine dependence	0.00224	0.00271	CcSEcCtD
Sitaxentan—Anorexia—Varenicline—nicotine dependence	0.00219	0.00266	CcSEcCtD
Sitaxentan—Hypotension—Varenicline—nicotine dependence	0.00215	0.00261	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—TAS2R16—nicotine dependence	0.0021	0.012	CbGpPWpGaD
Sitaxentan—Insomnia—Varenicline—nicotine dependence	0.00208	0.00252	CcSEcCtD
Sitaxentan—Somnolence—Varenicline—nicotine dependence	0.00205	0.00248	CcSEcCtD
Sitaxentan—Dyspepsia—Varenicline—nicotine dependence	0.00203	0.00246	CcSEcCtD
Sitaxentan—Decreased appetite—Varenicline—nicotine dependence	0.002	0.00243	CcSEcCtD
Sitaxentan—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00199	0.00241	CcSEcCtD
Sitaxentan—Fatigue—Varenicline—nicotine dependence	0.00198	0.00241	CcSEcCtD
Sitaxentan—Constipation—Varenicline—nicotine dependence	0.00197	0.00239	CcSEcCtD
Sitaxentan—Pain—Varenicline—nicotine dependence	0.00197	0.00239	CcSEcCtD
Sitaxentan—EDNRA—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00191	0.0109	CbGpPWpGaD
Sitaxentan—Feeling abnormal—Varenicline—nicotine dependence	0.0019	0.0023	CcSEcCtD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00185	0.0105	CbGpPWpGaD
Sitaxentan—Urticaria—Varenicline—nicotine dependence	0.00183	0.00222	CcSEcCtD
Sitaxentan—CYP3A4—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00182	0.0104	CbGpPWpGaD
Sitaxentan—Body temperature increased—Varenicline—nicotine dependence	0.00182	0.00221	CcSEcCtD
Sitaxentan—EDNRA—GPCR downstream signaling—FGD1—nicotine dependence	0.00182	0.0104	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—DRD2—nicotine dependence	0.00175	0.00996	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TAS2R16—nicotine dependence	0.00174	0.00991	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—OPRM1—nicotine dependence	0.00173	0.00986	CbGpPWpGaD
Sitaxentan—Hypersensitivity—Varenicline—nicotine dependence	0.0017	0.00206	CcSEcCtD
Sitaxentan—Asthenia—Varenicline—nicotine dependence	0.00165	0.002	CcSEcCtD
Sitaxentan—EDNRA—Signaling by GPCR—FGD1—nicotine dependence	0.00165	0.00942	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00164	0.00936	CbGpPWpGaD
Sitaxentan—Diarrhoea—Varenicline—nicotine dependence	0.00158	0.00191	CcSEcCtD
Sitaxentan—Dizziness—Varenicline—nicotine dependence	0.00152	0.00185	CcSEcCtD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0015	0.00854	CbGpPWpGaD
Sitaxentan—Vomiting—Varenicline—nicotine dependence	0.00146	0.00177	CcSEcCtD
Sitaxentan—Rash—Varenicline—nicotine dependence	0.00145	0.00176	CcSEcCtD
Sitaxentan—Dermatitis—Varenicline—nicotine dependence	0.00145	0.00176	CcSEcCtD
Sitaxentan—Headache—Varenicline—nicotine dependence	0.00144	0.00175	CcSEcCtD
Sitaxentan—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.0014	0.008	CbGpPWpGaD
Sitaxentan—Nausea—Varenicline—nicotine dependence	0.00137	0.00166	CcSEcCtD
Sitaxentan—EDNRB—GPCR downstream signaling—OPRM1—nicotine dependence	0.00136	0.00779	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—FGD1—nicotine dependence	0.00136	0.00777	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00132	0.00754	CbGpPWpGaD
Sitaxentan—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0013	0.00744	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00128	0.00729	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—DRD2—nicotine dependence	0.00125	0.00713	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TAS2R16—nicotine dependence	0.00124	0.00709	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—OPRM1—nicotine dependence	0.00124	0.00707	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.0012	0.00687	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—AKR1B10—nicotine dependence	0.0012	0.00687	CbGpPWpGaD
Sitaxentan—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00119	0.00678	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—DRD2—nicotine dependence	0.000987	0.00563	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—OPRM1—nicotine dependence	0.000977	0.00557	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—FGD1—nicotine dependence	0.000975	0.00556	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—DRD2—nicotine dependence	0.000896	0.00511	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—OPRM1—nicotine dependence	0.000887	0.00506	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—AKR1B10—nicotine dependence	0.000861	0.00492	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—WASF2—nicotine dependence	0.000848	0.00484	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—AKR1B10—nicotine dependence	0.000843	0.00481	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—WASF1—nicotine dependence	0.000813	0.00464	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—CYP2A7—nicotine dependence	0.000795	0.00453	CbGpPWpGaD
Sitaxentan—CYP3A4—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000784	0.00447	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—OPRM1—nicotine dependence	0.000732	0.00418	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—DRD2—nicotine dependence	0.000706	0.00403	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—DRD2—nicotine dependence	0.000641	0.00366	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—WASF2—nicotine dependence	0.000607	0.00346	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—WASF1—nicotine dependence	0.000582	0.00332	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—DRD2—nicotine dependence	0.000529	0.00302	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—OPRM1—nicotine dependence	0.000524	0.00299	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—DRD2—nicotine dependence	0.000379	0.00216	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.000226	0.00129	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000206	0.00118	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—CYP2A7—nicotine dependence	0.000136	0.000775	CbGpPWpGaD
